西妥昔单抗联合奥沙利铂治疗晚期胃癌的效果及对患者IGFBP3、HSP90水平的影响

Effect of cetuximab combined with oxaliplatin on advanced gastric cancer and its influence on levels of IGFBP3 and HSP90

目的探讨西妥昔单抗联合奥沙利铂治疗晚期胃癌的临床效果及对患者胰岛素样生长因子结合蛋白(IGFBP3)、热休克蛋白90(HSP90)水平的影响。方法抽取2016年2月至2021年2月南阳市中心医院收治的103例晚期胃癌患者为研究对象,按照治疗方法分为单药治疗组(47例)和联合治疗组(56例)。单药治疗组给予静脉滴注奥沙利铂,联合治疗组在单药治疗组基础上加用西妥昔单抗。比较两组近期疗效、免疫学指标及IGFBP3、HSP90水平。结果联合治疗组疾病控制率(87.50%,49/56)高于单药治疗组(68.09%,32/47),P<0.05;治疗后,两组免疫球蛋白A(IgA)、免疫球蛋白M(IgM)、免疫球蛋白G(IgG)水平均较治疗前降低,且联合治疗组IgA、IgM、IgG水平低于单药治疗组(P<0.05);两组IGFBP3水平均较治疗前升高,HSP90水平均较治疗前降低,且联合治疗组IGFBP3水平高于单药治疗组,HSP90水平低于单药治疗组(P<0.05)。联合治疗组总不良反应发生率(7.14%,4/56)低于单药治疗组(23.40%,11/47),P<0.05。结论西妥昔单抗联合奥沙利铂治疗晚期胃癌近期疗效显著,可提高患者的IGFBP3水平,降低HSP90水平,安全性高。

Objective To investigate the clinical effect of cetuximab combined with oxaliplatin in the treatment of advanced gastric cancer,and its influence on the levels of insulin-like growth factor binding protein 3(IGFBP3)and heat shock protein 90(HSP90).Methods A total of 103 patients with advanced gastric cancer treated in Nanyang Central Hospital from February 2016 to February 2021 were selected as the research objects.According to treatment methods,they were divided into single drug treatment group(47 cases)and combined treatment group(56 cases).The single drug treatment group received oxaliplatin intravenously,while the combined treatment group was treated with cetuximab based on the treatment of the single drug treatment group.The short-term efficacy,immunological indexes,and levels of IGFBP3 and HSP90 were compared between the two groups.Results The disease control rate in the combined treatment group(87.50%,49/56)was higher than that in the single drug treatment group(68.09%,32/47),P<0.05.After treatment,the levels of immunoglobulin A(IgA),immunoglobulin M(IgM)and immunoglobulin G(IgG)in the two groups were lower than those before treatment,and the levels of IgA,IgM and IgG in the combined treatment group were lower than those in the single drug treatment group(P<0.05).The IGFBP3 level of the two groups were higher than those before treatment,and the HSP90 level of the two groups were lower than those before treatment,the IGFBP3 level in the combined treatment group was higher than that in the single drug treatment group,and the HSP90 level was lower than that in the single drug treatment group(P<0.05).The total adverse reaction rate in the combined treatment group(7.14%,4/56)was lower than that in the single drug treatment group(23.40%,11/47),P<0.05 Conclusions The short-term efficacy of cetuximab combined with oxaliplatin in the treatment of advanced gastric cancer is significant,and the therapy can increase the level of IGFBP3 and reduce the level of HSP90 in patients,with high safety.